Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.42 |
| ▸ | QPCT | Q16769 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.37 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17151793 | 0.89 | MAP4K3 (0.48) | SLC6A2SLC6A4SLC6A3MAP4K3TLR9 | |
| SCHEMBL1765207 | 0.84 | MLYCD (0.46) | SLC6A2SLC6A4SLC6A3MLYCDQPCT | |
| SCHEMBL20924228 | 0.83 | HSD17B1 (0.47) | SLC6A2SLC6A4SLC6A3QPCTMAP4K3 | |
| SCHEMBL29786817 | 0.82 | KDR (0.46) | SLC6A2SLC6A4SLC6A3USP30 | |
| SCHEMBL21774242 | 0.79 | EGLN2 (0.40) | QPCTCTSCMAP4K3TLR9TLR8 | |
| SCHEMBL21774181 | 0.79 | QPCT (0.40) | SLC6A2SLC6A4SLC6A3QPCTCTSC | |
| SCHEMBL21774262 | 0.76 | CSNK2A1 (0.43) | QPCTHDAC3HDAC1HDAC6 | |
| SCHEMBL17151815 | 0.76 | POLB (0.49) | — | |
| SCHEMBL23040089 | 0.74 | IDO1 (0.48) | MLYCD | |
| SCHEMBL20500609 | 0.74 | MAP4K4 (0.45) | SLC6A2SLC6A4SLC6A3MLYCDQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SLC6A2 430/4885SLC6A4 781/4885SLC6A3 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.